Short answer
Upstream Bio, Inc. (UPB) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results and business highlights announced for quarter ended September 30, 2026.
Upstream Bio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results and business highlights announced for quarter ended September 30, 2026
- Detailed financial figures and operating updates contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 trials in severe asthma and CRSwNP planned for Q1 2027, advancing verekitug toward late-stage development
- Cash, equivalents and short-term investments $207.4M, expected to fund planned operations through 2027
- Q3 net loss $41.2M versus $33.7M, reflecting continued investment ahead of Phase 3 execution
- Q3 R&D expense $36.6M versus $33.0M, driven by personnel and verekitug clinical costs
- COPD Phase 2 VENTURE enrolled approximately 480 participants, with data expected in H2 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Upstream Bio, Inc. 8-K filings
Get the next UPB 8-K as it lands
Follow UPB for push alerts, or ask the research agent what this filing means.